LEUKEMIA SIGNALLING · Defining the functions of novel integral membrane regulator, CMTM family in B cell development and acute lymphoblastic leukemia
7РП — „Хора“ (Действия „Мария Кюри“)
- Период
- 2014-06-01 → 2016-11-30
- Финансиране от ЕС
- 299 558 €
- Участници
- 1
- Схема
- MC-IIF
Линиите свързват координатора с партньорите.
Накратко на български
Протеините от семейството CMTM и техните функции при развитието на B-клетките и острата лимфобластна левкемия се анализират в този проект. Работата помага да се разбере как сигналите в клетките и определени регулатори влияят върху развитието на рака.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Defining the functions of novel integral membrane regulator, CMTM family in B cell development and acute lymphoblastic leukemia
Findings from this research have been made available to the scientific community through timely publications and poster presentations at international conferences. Outreach activities were undertaken as a Marie Curie Ambassador to interact with children and the public to showcase the benefits and applications of cancer research. 1. In collaboration with research groups in Newcastle University, based on cell signalling expertise of the researcher, a first authored Spotlight Review on the role of pre-BCR checkpoint in B-ALL was published in Leukaemia, 2015. Eswaran et al., 2015 PMID: 25943180. 2. The researcher made significant contribution to data analysis and was co-author a publication entitled “Clinical and genetic landscapes differ between IGH-CRLF2 and P2RY8-CRLF2 acute lymphoblastic leukaemia”. Russell, et al Genes Chromosomes Cancer. 2016 Dec 29. doi: 10.1002/gcc.22439. 3. Similarly, through collaborative research projects, the researcher submitted a short report as corresponding author to Haematologica: BACH2 and BCL6 cooperatively functions as tumour suppressors in chronic lymphoblastic leukaemia. Ciardullo, et al. (2016). 4. Collaborative research projects on the impact of apoptotic regulators in CLL resulted poster presentations in 2016, British Society of Haematology and European Haematology Association: (A) Ciardullo, et al “Impact of the apoptotic regulator DRAK2 in Chronic Lymphocytic Leukaemia” British Society of Haematology. (B) Ciardullo, et al (Eswaran corresponding author) “BACH2–BCL6 cooperatively function as tumour suppressors in CLL, European Haematology Association. (C) Ciardullo, et al “Investigating the role of novel apoptotic regulator Drak2 in CLL, European Haematology Association. 5. The researcher established an international network of collaboration with many institutions in India, Malaysia, Indonesia and Thailand including Clinical Research Malaysia and Institute of Medical Research, with oral presentations given in Malaysia (A) Investigating the role of novel apoptotic regulator Drak2 in CLL”, at Universiti Sains Malaysia, Advanced Medical and Dental Institute Penang, Malaysia, 12th May 2016 (B) Overview on leukaemia research in Newcastle at Kuala Lumpar General Hospital, Malaysia, 16th May 2016. 6. With this network, MRC Global Research Challenges Foundation Award application was submitted jointly with Prof Christine Harrison and Malaysian collaborators. To strengthen collaborations, academic conference funding (£6000) was obtained to organise a collaborative meeting at Newcastle Malaysian Campus in collaboration with Prof Christine Harrison, Prof Andy Hall and Dr Michaela Goodson in 2017. 7. The following Outreach activities were undertaken as a Marie Curie Ambassador through STEMNET (Science, Technology, Engineering and Mathematics Network) Ambassador with DBS (Disclosure and Barring Service) clearance, which allowed work with school children in North East England who participated in (A) Makers Fair: whole day event on 24th April 2016 at Centre for Life showing applications of Light and Electromagnetic spectrum. We made a simple take away spectrometer and discussed its uses. (B) Big Bang Fair: whole day event on 27th June, at Northumbria University, on Healthy Eating and Chemistry Smells which introduced calories, healthy eating and Chemistry to year 4 and 5 school children. (C) Outreach activates for school children to meet scientists at the Great North Museum, Newcastle on March 31st 2015 as a Marie Curie Ambassador. (D) Showcasing Newcastle Childhood Cancer Research at the Blagdon Children's Cancer Walk on 20th Sept 2014 at Blagdon Estates, Newcastle. (E) Showcasing Newcastle Childhood Cancer Research on 7th September 2014 at the Great North Run 2014.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Despite the vast improvements in survival, acute lymphoblastic leukaemia (ALL) remains one of the major causes of death in children. The current combination chemotherapy causes acute and long-term toxicity. Hence, there is a compelling need to understand the development of ALL and identify key players that could be used in targeted therapy. The B cell receptor (BCR) and its precursor, pre-BCR, control the regulation of B cell differentiation and therefore aberrant pre-BCR and BCR functions results in B cell leukemia. The aim of my project is to identify new membrane associated drug targets for BCR-ALL therapy through investigating the functions of recently discovered Chemokine factor like Marvel like Trans Membrane proteins (CMTM) that interacts with the BCR and the intracellular adaptor, SLP-65, in B cell developmental process. To achieve this, I will employ multidisciplinary approaches and focus on the first B cell developmental checkpoint, the pre-BCR stage. The main objectives of the project are (i) to discover and characterize the CMTM mediated macro molecular assemblage using systems biology approach (ii) to identify the CMTM mediated downstream signaling network emanating from the pre BCR through cell biology and next generation sequencing methodologies and (iii) to determine the structures of pre BCR membrane/cytosolic multi protein CMTM mediated complexes using NMR or X-ray crystallography. Thus, the proposed project will discover the role of new membrane regulators in pre B cell development and pre BCR-ALL. I propose to set this previously not existing B cell membrane regulator research theme at Newcastle University, U.K. moving from my previous position at the George Washington University, USA. This program will open new avenues for B cell lineage ALL treatment and expand the scientific excellence of European cancer drug discovery research initiatives.
Оригинален текст от CORDIS (на английски).
Участници
- UNIVERSITY OF NEWCASTLE UPON TYNE · Newcastle Upon TyneКоординаторОбединеното кралство
Връзки
Данни: CORDIS, © Европейски съюз